NCT00485615

An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia

An Open-label, Pilot Study Evaluating the Efficacy of Enteric-coated Eicosapentaenoic Acid (o3mega+Joy) in the Treatment of Social Phobia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: START Clinic for Mood and Anxiety Disorders · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to evaluate the efficacy of an enteric-coated, eicosapentaenoic acid-concentrated fish oil in the treatment of social phobia. A secondary objective is to determine if treatment outcome is related to plasma phospholipid essential fatty acid status, niacin skin flush and measures of lipid/protein peroxidation.

Detailed description

Subjects meeting criteria for Social Anxiety Disorder, will receive enteric-coated, eicosapentaenoic acid-concentrated fish oil (O3mega+Joy) for 12 weeks of treatment for social phobia. A secondary objective is to determine if treatment outcome is related to changes in plasma phospholipid essential fatty acid status, niacin skin flush and measures of lipid/protein change.

Conditions

• Social Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Omega 3 Joy enteric coated concentrated fish oil	1500-3000mg; one per day

Timeline

• Start date: 2008-10-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2007-06-13
• Last updated: 2013-10-30

Locations

1 site across 1 country: Canada